Vivani Medical Inc. has released a presentation detailing its ongoing developments and future plans. The company is focused on creating ultra long-acting, miniature drug implants aimed at treating chronic diseases. Their NanoPortal platform technology is designed to improve medication adherence and tolerability. Key programs highlighted include NPM-115, a high-dose exenatide implant, and NPM-139, a semaglutide implant, both under development for chronic weight management in obese and overweight individuals with potential once or twice-yearly dosing. Additionally, the pipeline features NPM-119, an exenatide implant for type 2 diabetes, intended for twice-yearly dosing. Vivani anticipates significant milestones in 2025, including the completion of the First-in-human LIBERATE-1 trial and progress in the NPM-139 program. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。